Truist Financial Has Lowered Expectations for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price
Regeneron Pharmaceuticals (NASDAQ:REGN – Free Report) had its price objective reduced by Truist Financial from $975.00 to $940.00 in a research note released on Wednesday,Benzinga reports. Truist Financial currently has a buy rating on the biopharmaceutical company’s stock. A number of other research analysts also recently commented on the company. Canaccord Genuity Group raised Regeneron […]
Regeneron Pharmaceuticals (NASDAQ:REGN – Free Report) had its price objective reduced by Truist Financial from $975.00 to $940.00 in a research note released on Wednesday,Benzinga reports. Truist Financial currently has a buy rating on the biopharmaceutical company’s stock. A number of other research analysts also recently commented on the company. Canaccord Genuity Group raised Regeneron […]
